Literature DB >> 17272865

Methods of minimal residual disease (MRD) detection in childhood haematological malignancies.

Justyna Jółkowska1, Katarzyna Derwich, Małgorzata Dawidowska.   

Abstract

The appropriate management of haematological disorders must rely on a precise and long-term monitoring of the patient's response to chemotherapy and radiotherapy. Clinical data are not sufficient and that is why in the last decade it became the most important to improve the knowledge of haematological diseases on the basis of molecular techniques and molecular markers. The presence of residual malignant cells among normal cells is termed minimal residual disease (MRD). Nowadays a great progress has been made in the treatment of malignant diseases and in the development of reliable molecular techniques, which are characterised by high sensitivity (10-3- 10-6) and ability to distinguish between normal and malignant cells at diagnosis and during follow-up. Especially, MRD data based on quantitative analysis (RQ-PCR, RT-RQ-PCR) appear to be crucial for appropriate evaluation of treatment response in many haematological malignancies. Implementation of standardized approaches for MRD assessment into routine molecular diagnostics available in all oncohaematological centres should be regarded nowadays a crucial point in further MRD study development.

Entities:  

Mesh:

Year:  2007        PMID: 17272865     DOI: 10.1007/BF03194661

Source DB:  PubMed          Journal:  J Appl Genet        ISSN: 1234-1983            Impact factor:   2.653


  47 in total

1.  The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.

Authors:  V de Haas; W B Breunis; R Dee; O J H M Verhagen; W Kroes; E R van Wering; J J M van Dongen; H van den Berg; C E van der Schoot
Journal:  Br J Haematol       Date:  2002-01       Impact factor: 6.998

2.  High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

Authors:  Hélène Lapillonne; Aline Renneville; Anne Auvrignon; Cyril Flamant; Annick Blaise; Christine Perot; Jean-Luc Lai; Paola Ballerini; Françoise Mazingue; Sylvie Fasola; Axelle Dehée; Françoise Bellman; Mircéa Adam; Myriam Labopin; Luc Douay; Guy Leverger; Claude Preudhomme; Judith Landman-Parker
Journal:  J Clin Oncol       Date:  2006-04-01       Impact factor: 44.544

3.  Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.

Authors:  S P Dibenedetto; L Lo Nigro; S P Mayer; G Rovera; G Schilirò
Journal:  Blood       Date:  1997-08-01       Impact factor: 22.113

4.  Molecular detection of minimal residual disease for patients with leukaemia and lymphoma.

Authors:  R Liang; D Chan; Y L Kwong; V Chan
Journal:  Hong Kong Med J       Date:  1997-06       Impact factor: 2.227

5.  Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.

Authors:  Elaine Coustan-Smith; Jose Sancho; Michael L Hancock; Bassem I Razzouk; Raul C Ribeiro; Gaston K Rivera; Jeffrey E Rubnitz; John T Sandlund; Ching-Hon Pui; Dario Campana
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  Minimal residual disease (MRD) status prior to allogeneic stem cell transplantation is a powerful predictor for post-transplant outcome in children with ALL.

Authors:  P Bader; J Hancock; H Kreyenberg; N J Goulden; D Niethammer; A Oakhill; C G Steward; R Handgretinger; J F Beck; T Klingebiel
Journal:  Leukemia       Date:  2002-09       Impact factor: 11.528

7.  Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia.

Authors:  Mehmet Uzunel; Marie Jaksch; Jonas Mattsson; Olle Ringdén
Journal:  Br J Haematol       Date:  2003-09       Impact factor: 6.998

8.  Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.

Authors:  N C Cross; L Feng; A Chase; J Bungey; T P Hughes; J M Goldman
Journal:  Blood       Date:  1993-09-15       Impact factor: 22.113

9.  Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.

Authors:  G Germano; L del Giudice; S Palatron; E Giarin; G Cazzaniga; A Biondi; G Basso
Journal:  Leukemia       Date:  2003-08       Impact factor: 11.528

Review 10.  Detection of minimal residual disease in acute myelogenous leukemia.

Authors:  P Raanani; I Ben-Bassat
Journal:  Acta Haematol       Date:  2004       Impact factor: 2.195

View more
  5 in total

1.  Separating spermatogonia from cancer cells in contaminated prepubertal primate testis cell suspensions.

Authors:  Brian P Hermann; Meena Sukhwani; Jennifer Salati; Yi Sheng; Tianjiao Chu; Kyle E Orwig
Journal:  Hum Reprod       Date:  2011-10-20       Impact factor: 6.918

Review 2.  New advances on the expansion and storage of human spermatogonial stem cells.

Authors:  Kathleen Hwang; Dolores J Lamb
Journal:  Curr Opin Urol       Date:  2010-11       Impact factor: 2.309

3.  Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.

Authors:  Caroline Woehlecke; Susan Wittig; Juliane Sanft; Hermann Kreyenberg; Bernd Gruhn
Journal:  J Cancer Res Clin Oncol       Date:  2015-01-24       Impact factor: 4.553

Review 4.  Theranostic Potentials of Gold Nanomaterials in Hematological Malignancies.

Authors:  Md Salman Shakil; Mahruba Sultana Niloy; Kazi Mustafa Mahmud; Mohammad Amjad Kamal; Md Asiful Islam
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

Review 5.  Testicular tissue cryopreservation and spermatogonial stem cell transplantation to restore fertility: from bench to bedside.

Authors:  Hooman Sadri-Ardekani; Anthony Atala
Journal:  Stem Cell Res Ther       Date:  2014-05-28       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.